The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
In October the lead compound IMO2055 failed a phase II trial for renal cell carcinoma. What kept the stock from tanking more than 25% on the bad news, considering that the whole pipeline consists of related TLR9 agonists and antagonists? Probably the significant number of collaborations with big pharma which has kept the quarterly burn close to zero. A company which doesn't lose money will never go out of business, right? But naturally, when trials fail the next thing to go will be the partnerships. When collaboration revenues vanish then the burn will appear. And then the stock will drop.
Idera has been bouncing like a rubber ball. I'll rate it again once it exits the mid-zone of recent range.